Despite FDA resolution of GLP-1 drug shortages, compounded (non-FDA-approved) versions of semaglutide and tirzepatide remain widely sold through clinics and medical spas. Data presented at the Obesity Medicine Association annual meeting show some suppliers have inconsistent licensure or FDA disciplinary action. Researchers highlight ongoing safety and quality concerns with compounded GLP-1s.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.